Consolidated Results of Operations -
Three-Month Periods Ended December 31,
2024 and 2023:
KING OF
PRUSSIA, Pa., Feb. 26,
2025 /PRNewswire/ -- Universal Health Realty Income
Trust (NYSE:UHT) announced today that for the three-month period
ended December 31, 2024, net income was $4.7 million, or $.34 per diluted share, as compared to
$3.6 million, or $.26 per diluted share, during the fourth quarter
of 2023.
As reflected on the attached Schedule of Non-GAAP Supplemental
Information ("Supplemental Schedule"), our financial results for
the three-month period ended December 31,
2023 included a loss on divestiture of approximately
$232,000, or $.02 per diluted share, in connection with the
sale of a vacant specialty facility located in Corpus Christi, Texas, in December, 2023.
After adjusting our reported results for this loss on divestiture,
our adjusted net income was $3.8
million, or $.28 per diluted
share during the three-month period ended December 31, 2023.
The increase in our adjusted net income of $836,000, or $.06
per diluted share, during the three-month period ended December 31, 2024, as compared to the fourth
quarter of 2023, consisted of the following: (i) an increase of
$1.2 million, or $.08 per diluted share, resulting from an
aggregate net increase in the income generated at various
properties, partially offset by; (ii) a decrease of $337,000, or $.02
per diluted share, resulting from an increase in interest expense
due primarily to increases in our average effective borrowing rate
(which gives effect to various interest rate swap agreements) and
our average outstanding borrowings pursuant to the terms of our
revolving credit agreement.
As calculated on the attached Supplemental Schedule, our funds
from operations ("FFO") were $11.8
million, or $.85 per diluted
share, during the fourth quarter of 2024, as compared to
$11.4 million, or $.82 per diluted share, during the fourth quarter
of 2023. The increase of $374,000, or
$.03 per diluted share, was due
primarily to the above-mentioned increase in our adjusted net
income during the fourth quarter of 2024, as compared to the fourth
quarter of 2023, partially offset by a decrease in depreciation and
amortization expense.
Consolidated Results of Operations - Twelve-Month Periods
Ended December 31, 2024 and
2023:
For the twelve-month period ended December 31, 2024, net income was $19.2 million, or $1.39 per diluted share, as compared to
$15.4 million, or $1.11 per diluted share during the full year of
2023.
As reflected on the Supplemental Schedule, our financial results
for the year ended December 31, 2023
included the above-mentioned loss on divestiture of real estate
assets of approximately $232,000
recorded during the fourth quarter of 2023. After adjusting our
reported results for the loss on divestiture, our adjusted net
income was $15.6 million, or
$1.13 per diluted share during the
year ended December 31, 2023.
The increase in our adjusted net income of $3.6 million, or $.26 per diluted share, during the year ended
December 31, 2024, as compared to the
comparable period of 2023, consisted of the following: (i) an
increase of $3.5 million, or
$.26 per diluted share, resulting
from an aggregate net increase in the income generated at various
properties; (ii) an increase of $2.0
million, or $.14 per diluted
share, resulting from a reduction in the expenses related to our
property located in Chicago,
Illinois, including $1.1
million from demolition expenses incurred during the twelve
months of 2023, and $610,000 related
to a property tax reduction recorded during the year ended
December 31, 2024 which related
primarily to prior periods, partially offset by; (iii) a decrease
of $1.9 million, or $.14 per diluted share, resulting from an
increase in interest expense due primarily to increases in our
average effective borrowing rate (which gives effect to various
interest rate swap agreements) and our average outstanding
borrowings pursuant to the terms of our revolving credit
agreement.
As calculated on the attached Supplemental Schedule, our FFO
were $47.9 million, or $3.46 per diluted share, during the year ended
December 31, 2024, as compared to
$44.6 million, or $3.23 per diluted share during the comparable
period of 2023. The increase of $3.3
million, or $.23 per diluted
share, was due primarily to the above-mentioned increase in our
adjusted net income during the year ended December 31, 2024, as compared to the year ended
December 31, 2023, partially offset
by a decrease in depreciation and amortization
expense.
Dividend Information:
The fourth quarter dividend of $.735 per share, or $10.1
million in the aggregate, was declared on November 25, 2024 and paid on December 31, 2024.
Capital Resources and Financial Instruments:
On September 30, 2024, we entered
into a second amended and restated credit agreement which increased
the borrowing capacity to $425
million (from $375 million
previously) and extended the maturity date to September 30, 2028 (from July, 2025
previously). We have the option to extend the maturity date
for up to two additional six-month periods.
At December 31, 2024, we had
$348.9 million of borrowings
outstanding pursuant to the terms of our $425 million revolving credit agreement and
$76.1 million of available borrowing
capacity as of that date, net of outstanding borrowings.
In October, 2024, we entered into an interest rate swap
agreement on a total notional amount of $85
million with a fixed interest rate of 3.2725% that we
designated as a cash flow hedge. The interest rate swap became
effective on October 2, 2024 and is
scheduled to mature on September 30,
2028. If one-month term SOFR is above 3.2725%, the
counterparty pays us, and if one-month term SOFR is less than
3.2725%, we pay the counterparty the difference between the fixed
rate of 3.2725% and one-month term SOFR.
This interest rate swap agreement replaced two interest rate
swaps agreements that expired on September
16, 2024 with a combined aggregate notional amount of
$85 million and a combined average
fixed interest rate of 1.21%.
Sierra Medical Plaza I:
In March, 2023, construction was substantially completed on the
Sierra Medical Plaza I, an 86,000 rentable square foot MOB located
in Reno, Nevada. This MOB is
located on the campus of the Northern Nevada Sierra Medical Center,
a hospital that is owned and operated by a wholly-owned subsidiary
of UHS, which was completed and opened during April, 2022. The MOB
is 68% leased including a ten-year master flex lease for 34% of the
rentable square feet. The master flex lease agreement is subject to
reduction based upon the execution of third-party leases The
aggregate cost of the MOB is estimated to be approximately
$35 million, approximately
$30 million of which was incurred as
of December 31, 2024.
Vacant Land/Specialty Facilities:
Demolition of the former specialty hospital located in
Chicago, Illinois, was completed
during 2023. The aggregate demolition expenses amounted to
approximately $1.5 million
($1.1 million of which were incurred
during the first and second quarters of 2023 and $332,000 of which were incurred during the fourth
quarter of 2022).
We continue to market the vacant properties located in
Chicago, Illinois and Evansville, Indiana. Future operating expenses
related to these properties, will be incurred by us during the time
they remain owned and unleased.
In December, 2023, we sold the vacant specialty facility in
Corpus Christi, Texas, for
proceeds of approximately $3.9
million, net of closing costs. This divestiture generated a
loss of approximately $232,000 which
is included in our consolidated statements of income for the three
and twelve-month periods ended December 31,
2023.
General Information, Forward-Looking Statements and Risk
Factors and Non-GAAP Financial Measures:
Universal Health Realty Income Trust, a real estate investment
trust, invests in healthcare and human-service related facilities
including acute care hospitals, behavioral health care hospitals,
specialty facilities, medical/office buildings, free-standing
emergency departments and childcare centers. We have investments or
commitments in seventy-six properties located in twenty-one
states.
This press release contains forward-looking statements based on
current management expectations. Numerous factors, including those
disclosed herein, as well as the operations and financial results
of each of our tenants, those related to healthcare industry trends
and those detailed in our filings with the Securities and Exchange
Commission (as set forth in Item 1A-Risk Factors and
in Item 7 - Forward-Looking Statements in our Form 10-K for
the year ended December 31, 2024),
may cause the results to differ materially from those anticipated
in the forward-looking statements. Readers should not place undue
reliance on such forward-looking statements which reflect
management's view only as of the date hereof. We undertake no
obligation to revise or update any forward-looking statements, or
to make any other forward-looking statements, whether as a result
of new information, future events or otherwise.
Many of the factors that could affect our future results are
beyond our control or ability to predict. Future operations and
financial results of our tenants, and in turn ours, could be
materially impacted by various developments including, but not
limited to, decreases in staffing availability and related
increases to wage expense experienced by our tenants resulting from
the shortage of nurses and other clinical staff and support
personnel, the impact of government and administrative regulation
of the health care industry; declining patient volumes and
unfavorable changes in payer mix caused by deteriorating
macroeconomic conditions (including increases in uninsured and
underinsured patients as the result of business closings and
layoffs); potential disruptions related to supplies required for
our tenants' employees and patients; and potential increases to
other expenditures.
In addition, the increase in interest rates has substantially
increased our borrowings costs and reduced our ability to access
the capital markets on favorable terms. Additional increases
in interest rates could have a significant unfavorable impact on
our future results of operations and the resulting effect on the
capital markets could adversely affect our ability to carry out our
strategy.
We believe that, if and when applicable, adjusted net income and
adjusted net income per diluted share (as reflected on the
Supplemental Schedule), which are non-GAAP financial measures
("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to
our investors as measures of our operating performance. In
addition, we believe that, when applicable, comparing and
discussing our financial results based on these measures, as
calculated, is helpful to our investors since it neutralizes the
effect in each year of material items that are non-recurring or
non-operational in nature including items such as, but not limited
to, gains or losses on transactions.
Funds from operations ("FFO") is a widely recognized measure of
performance for Real Estate Investment Trusts ("REITs"). We believe
that FFO and FFO per diluted share, which are non-GAAP financial
measures, are helpful to our investors as measures of our operating
performance. We compute FFO, as reflected on the attached
Supplemental Schedules, in accordance with standards established by
the National Association of Real Estate Investment Trusts
("NAREIT"), which may not be comparable to FFO reported by other
REITs that do not compute FFO in accordance with the NAREIT
definition, or that interpret the NAREIT definition differently
than we interpret the definition. FFO adjusts for the effects of
certain items, such as gains or losses on transactions that
occurred during the periods presented. FFO does not represent
cash generated from operating activities in accordance with GAAP
and should not be considered to be an alternative to net income
determined in accordance with GAAP. In addition, FFO should not be
used as: (i) an indication of our financial performance determined
in accordance with GAAP; (ii) an alternative to cash flow from
operating activities determined in accordance with GAAP; (iii) a
measure of our liquidity, or; (iv) an indicator of funds available
for our cash needs, including our ability to make cash
distributions to shareholders. A reconciliation of our reported net
income to FFO is reflected on the Supplemental Schedules included
below.
To obtain a complete understanding of our financial performance
these measures should be examined in connection with net income,
determined in accordance with GAAP, as presented in the condensed
consolidated financial statements and notes thereto in this report
or in our other filings with the Securities and Exchange Commission
including our Report on Form 10-K for the year ended December 31, 2024 Since the items included or
excluded from these measures are significant components in
understanding and assessing financial performance under GAAP, these
measures should not be considered to be alternatives to net income
as a measure of our operating performance or profitability. Since
these measures, as presented, are not determined in accordance with
GAAP and are thus susceptible to varying calculations, they may not
be comparable to other similarly titled measures of other
companies. Investors are encouraged to use GAAP measures when
evaluating our financial performance.
Universal Health
Realty Income Trust
Consolidated Statements
of Income
For the Three and
Twelve Months Ended December 31, 2024 and 2023
(amounts in thousands,
except share information)
(unaudited)
|
|
|
|
Three Months
Ended
|
|
|
Twelve Months
Ended
|
|
|
|
December
31,
|
|
|
December
31,
|
|
|
|
2024
|
|
|
2023
|
|
|
2024
|
|
|
2023
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
Lease revenue -
UHS facilities (a.)
|
|
$
|
8,261
|
|
|
$
|
8,326
|
|
|
$
|
33,627
|
|
|
$
|
32,623
|
|
Lease revenue -
Non-related parties
|
|
|
14,472
|
|
|
|
14,038
|
|
|
|
57,660
|
|
|
|
54,993
|
|
Other revenue -
UHS facilities
|
|
|
220
|
|
|
|
216
|
|
|
|
902
|
|
|
|
946
|
|
Other revenue -
Non-related parties
|
|
|
334
|
|
|
|
378
|
|
|
|
1,390
|
|
|
|
1,555
|
|
Interest income
on financing leases - UHS facilities
|
|
|
1,355
|
|
|
|
1,362
|
|
|
|
5,432
|
|
|
|
5,458
|
|
|
|
|
24,642
|
|
|
|
24,320
|
|
|
|
99,011
|
|
|
|
95,575
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
and amortization
|
|
|
6,797
|
|
|
|
7,254
|
|
|
|
27,421
|
|
|
|
27,733
|
|
Advisory fees
to UHS
|
|
|
1,388
|
|
|
|
1,366
|
|
|
|
5,481
|
|
|
|
5,323
|
|
Other operating
expenses
|
|
|
7,198
|
|
|
|
7,545
|
|
|
|
29,313
|
|
|
|
31,170
|
|
|
|
|
15,383
|
|
|
|
16,165
|
|
|
|
62,215
|
|
|
|
64,226
|
|
Income before equity in
income of unconsolidated limited
liability companies
("LLCs"), loss on divestiture and
interest
expense
|
|
|
9,259
|
|
|
|
8,155
|
|
|
|
36,796
|
|
|
|
31,349
|
|
Equity in
income of unconsolidated LLCs
|
|
|
323
|
|
|
|
254
|
|
|
|
1,279
|
|
|
|
1,207
|
|
Loss on
divestiture of real estate assets
|
|
|
-
|
|
|
|
(232)
|
|
|
|
-
|
|
|
|
(232)
|
|
Interest
expense, net
|
|
|
(4,921)
|
|
|
|
(4,584)
|
|
|
|
(18,841)
|
|
|
|
(16,924)
|
|
Net income
|
|
$
|
4,661
|
|
|
$
|
3,593
|
|
|
$
|
19,234
|
|
|
$
|
15,400
|
|
Basic earnings per
share
|
|
$
|
0.34
|
|
|
$
|
0.26
|
|
|
$
|
1.39
|
|
|
$
|
1.12
|
|
Diluted earnings per
share
|
|
$
|
0.34
|
|
|
$
|
0.26
|
|
|
$
|
1.39
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number
of shares outstanding - Basic
|
|
|
13,809
|
|
|
|
13,791
|
|
|
|
13,802
|
|
|
|
13,786
|
|
Weighted average number
of shares outstanding - Diluted
|
|
|
13,850
|
|
|
|
13,823
|
|
|
|
13,839
|
|
|
|
13,814
|
|
(a.) Includes bonus
rental on McAllen Medical Center, a UHS acute care hospital
facility, of $801 and $734 for the three-month
periods ended December
31, 2024 and 2023, respectively, and $3,107 and $2,953 for the
twelve-month periods ended December
31, 2024 and 2023,
respectively.
|
Universal Health
Realty Income Trust
Schedule of Non-GAAP
Supplemental Information ("Supplemental Schedule")
For the Three Months
Ended December 31, 2024 and 2023
(amounts in thousands,
except share information)
(unaudited)
|
|
Calculation of
Adjusted Net Income
|
|
|
|
Three Months
Ended
|
|
|
Three Months
Ended
|
|
|
|
December 31,
2024
|
|
|
December 31,
2023
|
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
Net income
|
|
$
|
4,661
|
|
|
$
|
0.34
|
|
|
$
|
3,593
|
|
|
$
|
0.26
|
|
Adjustment:
|
|
|
|
|
|
|
|
|
|
|
|
|
Plus: Loss on
divestiture of real estate assets
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
Subtotal adjustments to
net income
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
Adjusted net
income
|
|
$
|
4,661
|
|
|
$
|
0.34
|
|
|
$
|
3,825
|
|
|
$
|
0.28
|
|
|
|
Calculation of Funds
From Operations ("FFO")
|
|
|
|
Three Months
Ended
|
|
|
Three Months
Ended
|
|
|
|
December 31,
2024
|
|
|
December 31,
2023
|
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
Net income
|
|
$
|
4,661
|
|
|
$
|
0.34
|
|
|
$
|
3,593
|
|
|
$
|
0.26
|
|
Plus: Depreciation and
amortization expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
investments
|
|
|
6,797
|
|
|
|
0.49
|
|
|
|
7,254
|
|
|
|
0.52
|
|
Unconsolidated
affiliates
|
|
|
300
|
|
|
|
0.02
|
|
|
|
305
|
|
|
|
0.02
|
|
Plus: Loss on
divestiture of real estate assets
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
FFO
|
|
$
|
11,758
|
|
|
$
|
0.85
|
|
|
$
|
11,384
|
|
|
$
|
0.82
|
|
Dividend paid per
share
|
|
|
|
|
$
|
0.735
|
|
|
|
|
|
$
|
0.725
|
|
Universal Health
Realty Income Trust
Schedule of Non-GAAP
Supplemental Information ("Supplemental Schedule")
For the Twelve Months
Ended December 31, 2024 and 2023
(amounts in thousands,
except share information)
(unaudited)
|
|
Calculation of
Adjusted Net Income
|
|
|
|
Twelve Months
Ended
|
|
|
Twelve Months
Ended
|
|
|
|
December 31,
2024
|
|
|
December 31,
2023
|
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
Net income
|
|
$
|
19,234
|
|
|
$
|
1.39
|
|
|
$
|
15,400
|
|
|
$
|
1.11
|
|
Adjustment:
|
|
|
|
|
|
|
|
|
|
|
|
|
Plus: Loss on
divestiture of real estate assets
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
Subtotal adjustments to
net income
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
Adjusted net
income
|
|
$
|
19,234
|
|
|
$
|
1.39
|
|
|
$
|
15,632
|
|
|
$
|
1.13
|
|
|
|
Calculation of Funds
From Operations ("FFO")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Twelve Months
Ended
|
|
|
Twelve Months
Ended
|
|
|
|
December 31,
2024
|
|
|
December 31,
2023
|
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
|
Amount
|
|
|
Per
Diluted Share
|
|
Net income
|
|
$
|
19,234
|
|
|
$
|
1.39
|
|
|
$
|
15,400
|
|
|
$
|
1.11
|
|
Plus: Depreciation and
amortization expense:
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
investments
|
|
|
27,421
|
|
|
|
1.98
|
|
|
|
27,733
|
|
|
|
2.01
|
|
Unconsolidated
affiliates
|
|
|
1,218
|
|
|
|
0.09
|
|
|
|
1,205
|
|
|
|
0.09
|
|
Plus: Loss on
divestiture of real estate assets
|
|
|
-
|
|
|
|
-
|
|
|
|
232
|
|
|
|
0.02
|
|
FFO
|
|
$
|
47,873
|
|
|
$
|
3.46
|
|
|
$
|
44,570
|
|
|
$
|
3.23
|
|
Dividend paid per
share
|
|
|
|
|
$
|
2.920
|
|
|
|
|
|
$
|
2.880
|
|
Universal Health
Realty Income Trust
Consolidated Balance
Sheets
(amounts in thousands,
except share information)
(unaudited)
|
|
|
|
December
31,
|
|
|
December
31,
|
|
|
|
2024
|
|
|
2023
|
|
Assets:
|
|
|
|
|
|
|
Real Estate
Investments:
|
|
|
|
|
|
|
Buildings and
improvements and construction in progress
|
|
$
|
655,996
|
|
|
$
|
649,374
|
|
Accumulated
depreciation
|
|
|
(286,932)
|
|
|
|
(262,449)
|
|
|
|
|
369,064
|
|
|
|
386,925
|
|
Land
|
|
|
56,870
|
|
|
|
56,870
|
|
Net Real Estate Investments
|
|
|
425,934
|
|
|
|
443,795
|
|
Financing receivable
from UHS
|
|
|
82,798
|
|
|
|
83,279
|
|
Net Real Estate Investments and Financing receivable
|
|
|
508,732
|
|
|
|
527,074
|
|
Investments in limited
liability companies ("LLCs")
|
|
|
13,948
|
|
|
|
9,102
|
|
Other
Assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
|
7,097
|
|
|
|
8,212
|
|
Lease and other
receivables from UHS
|
|
|
7,131
|
|
|
|
6,180
|
|
Lease receivable -
other
|
|
|
7,975
|
|
|
|
8,166
|
|
Intangible assets (net
of accumulated amortization of $11.3 million and
$12.5 million, respectively)
|
|
|
7,325
|
|
|
|
9,110
|
|
Right-of-use land
assets, net
|
|
|
10,918
|
|
|
|
10,946
|
|
Deferred charges,
notes receivable and other assets, net
|
|
|
17,736
|
|
|
|
17,579
|
|
Total Assets
|
|
$
|
580,862
|
|
|
$
|
596,369
|
|
Liabilities:
|
|
|
|
|
|
|
Line of credit
borrowings
|
|
$
|
348,900
|
|
|
$
|
326,600
|
|
Mortgage notes
payable, non-recourse to us, net
|
|
|
19,349
|
|
|
|
32,863
|
|
Accrued
interest
|
|
|
694
|
|
|
|
490
|
|
Accrued expenses and
other liabilities
|
|
|
10,444
|
|
|
|
13,500
|
|
Ground lease
liabilities, net
|
|
|
10,918
|
|
|
|
10,946
|
|
Tenant reserves,
deposits and deferred and prepaid rents
|
|
|
11,016
|
|
|
|
11,036
|
|
Total Liabilities
|
|
|
401,321
|
|
|
|
395,435
|
|
Equity:
|
|
|
|
|
|
|
Preferred shares of
beneficial interest,
$.01 par value; 5,000,000 shares authorized;
none issued and outstanding
|
|
|
-
|
|
|
|
-
|
|
Common shares, $.01
par value;
95,000,000 shares authorized; issued and outstanding:
2024 - 13,850,608;
2023 - 13,823,899
|
|
|
138
|
|
|
|
138
|
|
Capital in excess of
par value
|
|
|
271,092
|
|
|
|
270,398
|
|
Cumulative net
income
|
|
|
845,295
|
|
|
|
826,061
|
|
Cumulative
dividends
|
|
|
(943,396)
|
|
|
|
(902,975)
|
|
Accumulated other
comprehensive income
|
|
|
6,412
|
|
|
|
7,312
|
|
Total Equity
|
|
|
179,541
|
|
|
|
200,934
|
|
Total Liabilities and Equity
|
|
$
|
580,862
|
|
|
$
|
596,369
|
|
View original
content:https://www.prnewswire.com/news-releases/universal-health-realty-income-trust-reports-2024-fourth-quarter-and-full-year-financial-results-302386572.html
SOURCE Universal Health Realty Income Trust